Time to Market refers to the duration between the conception of a product or service and its availability for sale or use in the market. In the context of clinical research and pharmaceutical development, it specifically relates to the time taken from the initial discovery of a drug compound to its commercial launch after regulatory approval.
This metric is crucial in the pharmaceutical industry as it directly impacts a company’s competitive advantage and potential revenue. A shorter Time to Market can mean earlier access to treatments for patients, increased market share for the company, and a longer period of patent exclusivity before generic competitors enter the market.
Time to Market is crucial in clinical research as it directly impacts the financial viability of drug development projects. Faster development timelines can lead to earlier market entry, potentially increasing the return on investment and providing a competitive edge in the pharmaceutical industry.
Moreover, a reduced Time to Market can accelerate patient access to new therapies, potentially saving lives and improving health outcomes. It also allows pharmaceutical companies to maximize the effective patent life of their products, ensuring a longer period of market exclusivity before generic competition emerges.
A recent publication in npj Digital Medicine explored the use of AI-generated radiology reports — and the results are worth…
The Axcellant team recently traveled to New York to meet with research partners and clinical collaborators from across the U.S.…
What Are Nuclear Medicine Procedures and How Are They Used in Clinical Trials? Nuclear medicine procedures (NMPs) are diagnostic and/or…
Copyright @ 2025 Axcellant